Life Biosciences has received FDA clearance for its Investigational New Drug application for ER-100, a cellular rejuvenation therapy aimed at treating optic neuropathies, marking a significant advancement in the treatment of age-related vision loss.
Life Biosciences, Inc., a biotechnology company focused on developing cellular rejuvenation therapies, announced on October 23, 2023, that the U.S. Food and Drug Administration (FDA) has granted clearance for its Investigational New Drug (IND) application for ER-100. This crucial approval allows Life Biosciences to commence clinical trials aimed at assessing the safety and potential efficacy of ER-100 for improving vision in patients suffering from optic neuropathies, conditions that lead to irreversible vision loss.
The Phase 1 clinical study, registered under the identifier NCT07290244, will enroll individuals diagnosed with open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION). The trial aims to evaluate the safety, tolerability, immune responses, and overall impact of ER-100 on various visual assessments. The initiation of this study represents a notable step forward in addressing the significant unmet medical need for effective treatments in this area.
Background on ER-100 and Its Mechanism
ER-100 is developed from Life Biosciences’ innovative Partial Epigenetic Reprogramming (PER) platform. This platform is designed to rejuvenate aged or injured cells by modifying the epigenome, which consists of biochemical markers that regulate gene expression without altering the DNA sequence itself. Life Biosciences’ approach enables the controlled expression of three of the four Yamanaka factors—OCT-4, SOX-2, and KLF-4 (collectively referred to as OSK). This mechanism was shown to enhance cellular function in preclinical studies conducted in animal models, particularly through local injection into the eye (intravitreally).
Dr. Sharon Rosenzweig-Lipson, Chief Scientific Officer of Life Biosciences, stated, “This important milestone in reaching the clinic is the result of years of research, optimization, and comprehensive nonhuman primate studies demonstrating controlled OSK expression, restoration of methylation patterns, and improved visual function, all of which has culminated in this IND clearance. These results have paved the way for first-in-human evaluation of our cellular rejuvenation approach with the goal of improving the lives of people facing debilitating age-related disease, starting with optic neuropathies.”
Understanding Optic Neuropathies
Optic neuropathies represent a group of disorders characterized by the irreversible degeneration of retinal ganglion cells (RGCs), which are essential neurons connecting the eye to the brain. The inability of RGCs to regenerate leads to permanent vision impairment. Open-angle glaucoma (OAG) is one of the most prevalent chronic neurodegenerative diseases and is a leading cause of blindness globally. This condition often correlates with elevated intraocular pressure, but RGC damage can persist even in patients with normal pressure levels, complicating treatment options.
On the other hand, non-arteritic anterior ischemic optic neuropathy (NAION), commonly referred to as a “stroke of the eye,” is the most frequent form of acute optic neuropathy in individuals over the age of fifty. NAION results in sudden, painless vision loss due to insufficient blood flow to the optic nerve, and currently, there are no FDA-approved treatments available for this condition. Both OAG and NAION see increased prevalence with age, leading to a growing global health concern. Existing treatment options largely fail to address the underlying neuronal degeneration, highlighting the urgent need for disease-modifying therapies that can protect or regenerate RGCs to restore or maintain sight.
Market Implications and Future Directions
The clearance of ER-100 for clinical trials is a pivotal moment not only for Life Biosciences but also for the field of age-related therapies. As the global population ages, the burden of diseases such as OAG and NAION is anticipated to rise, creating a pressing demand for innovative treatment solutions. Current therapeutic approaches primarily focus on managing symptoms rather than reversing the underlying pathophysiology, which underscores the significance of Life Biosciences’ efforts to pioneer a fundamentally different treatment paradigm.
Life Biosciences is positioned as a clinical-stage biotechnology company that aims to develop cellular rejuvenation therapies targeting multiple age-related diseases. The company’s proprietary Partial Epigenetic Reprogramming (PER) platform employs the transcription factors OCT4, SOX2, and KLF4 to restore older or damaged cells to a more youthful and healthier state. This innovative methodology targets the root causes of aging at the epigenetic level and holds promise for addressing a wide range of serious age-related conditions. ER-100 is just the beginning, as Life Biosciences has plans to broaden its pipeline to include therapies for other age-related diseases, underscoring the platform’s versatility and transformative potential.
Looking ahead, the company plans to initiate the Phase 1 clinical trial for ER-100 in the first quarter of 2026. This timeline indicates a commitment to rapid advancement in the research and development of therapies that could significantly impact patients’ lives. As ER-100 moves into the clinical testing phase, the scientific community and patients alike will be closely monitoring the outcomes as they may set a new standard for the treatment of optic neuropathies.
For further information on Life Biosciences and its ongoing research initiatives, interested parties can visit www.lifebiosciences.com or follow the company on social media platforms such as Twitter (X) and LinkedIn.
No Comment! Be the first one.